Nanobiotix sai ensi neljänneksellä 86,1 miljoonaa euroa ja eteni syöpätutkimuksessa
Biotechnology company Nanobiotix reported first quarter 2026 financial results. The company raised approximately €86.1 million from a May follow-on offering and presented new data on its cancer therapy NBTXR3.
Nanobiotix, a biotechnology firm specializing in nanotherapeutics, announced its operational and financial results for the first quarter of 2026. The company secured approximately €86.1 million in gross proceeds through a follow-on offering in May, which included pre-funded warrants aimed at accelerating the development of its various platforms.
Operational updates highlighted the presentation of new data from the Phase 2 CONVERGE study evaluating NBTXR3 for inoperable non-small cell lung cancer (NSCLC) at the 2026 European Society for Radiotherapy and Oncology (ESTRO) annual meeting. Initial results from Part 1 of the study indicated promising efficacy, with an overall response rate of 85.7% and a complete response rate of 57.1% in a cohort of seven patients receiving NBTXR3 alongside chemoradiotherapy and consolidation with durvalumab.
The company also reported that the U.S. Food and Drug Administration (FDA) accepted a protocol amendment for the pivotal NANORAY-312 study. This amendment modifies the final analysis to be conducted sooner and include fewer events than originally planned. Furthermore, Nanobiotix presented preclinical data on its Nanoprimer platform, demonstrating its potential to enhance the systemic bioavailability and reduce toxicity of lipid nanoparticle-delivered DNA for anti-tumor immunotherapy.
As of March 31, 2026, Nanobiotix reported €42.1 million in cash and cash equivalents. The company stated that, combined with the proceeds from the recent offering, these funds are expected to cover its working capital requirements into 2029, based on its current anticipated cash burn rate.